PMID- 28572467
OWN - NLM
STAT- MEDLINE
DCOM- 20180502
LR  - 20181008
IS  - 1499-2752 (Electronic)
IS  - 0315-162X (Linking)
VI  - 44
IP  - 8
DP  - 2017 Aug
TI  - Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with 
      csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
PG  - 1159-1164
LID - 10.3899/jrheum.170112 [doi]
AB  - OBJECTIVE: In a complex disease such as psoriatic arthritis (PsA), several 
      methods are available to define remission or low disease activity (LDA), 
      including the assessment of different clinical features. The aim of this study 
      was to compare the composite indices tailored for PsA in patients treated with 
      conventional synthetic disease-modifying antirheumatic drugs (csDMARD) and 
      biological DMARD (bDMARD). METHODS: Patients with PsA classified with the 
      ClASsification criteria for Psoriatic ARthritis criteria and with > 6 months 
      followup treated with first csDMARD and bDMARD were consecutively enrolled. To 
      assess disease activity, composite indices tailored for PsA were used, such as 
      the Disease Activity Index for Psoriatic Arthritis (DAPSA), clinical DAPSA 
      (cDAPSA), Psoriatic Arthritis Disease Activity Score (PASDAS), minimal disease 
      activity (MDA) 5/7, and MDA 7/7. DAPSA and cDAPSA score </= 4, MDA 7/7, and PASDAS 
      </= 1.9 identified remission. MDA 5/7, DAPSA score </= 14, cDAPSA score </= 13, and 
      PASDAS < 3.2 identified the MDA and LDA criteria. RESULTS: One hundred nine 
      patients with PsA were enrolled: 79 patients were receiving stable treatment with 
      bDMARD and 30 with csDMARD. Overall, 28 (25.6%), 23 (21.1%), 19 (17.4%), and 13 
      patients (11.9%) were in cDAPSA remission, DAPSA remission, MDA 7/7, and PASDAS </= 
      1.9, respectively. Moreover, 54 (49.5%), 80 (73.3%), 79 (72.3%), and 38 patients 
      (34.8%) were in MDA 5/7, DAPSA LDA, cDAPSA LDA, and PASDAS LDA. Patients treated 
      with bDMARD had significantly lower median DAPSA, cDAPSA, and PASDAS score than 
      patients treated with csDMARD. CONCLUSION: Patients with PsA receiving bDMARD are 
      more likely to achieve a status of MDA and remission when compared with csDMARD. 
      PASDAS </= 1.9 and MDA 7/7 seem to be stringent remission criteria.
FAU - Lubrano, Ennio
AU  - Lubrano E
AD  - From the Dipartimento di Medicina e Scienze della Salute Vincenzo Tiberio, 
      Universita degli Studi del Molise, Campobasso, Italy. enniolubrano@hotmail.com.
AD  - E. Lubrano, MD, PhD, Dipartimento di Medicina e Scienze della Salute Vincenzo 
      Tiberio, Universita degli Studi del Molise; A. De Socio, MD, Dipartimento di 
      Medicina e Scienze della Salute Vincenzo Tiberio, Universita degli Studi del 
      Molise; F.M. Perrotta, MD, Dipartimento di Medicina e Scienze della Salute 
      Vincenzo Tiberio, Universita degli Studi del Molise. enniolubrano@hotmail.com.
FAU - De Socio, Antonia
AU  - De Socio A
AD  - From the Dipartimento di Medicina e Scienze della Salute Vincenzo Tiberio, 
      Universita degli Studi del Molise, Campobasso, Italy.
AD  - E. Lubrano, MD, PhD, Dipartimento di Medicina e Scienze della Salute Vincenzo 
      Tiberio, Universita degli Studi del Molise; A. De Socio, MD, Dipartimento di 
      Medicina e Scienze della Salute Vincenzo Tiberio, Universita degli Studi del 
      Molise; F.M. Perrotta, MD, Dipartimento di Medicina e Scienze della Salute 
      Vincenzo Tiberio, Universita degli Studi del Molise.
FAU - Perrotta, Fabio Massimo
AU  - Perrotta FM
AD  - From the Dipartimento di Medicina e Scienze della Salute Vincenzo Tiberio, 
      Universita degli Studi del Molise, Campobasso, Italy.
AD  - E. Lubrano, MD, PhD, Dipartimento di Medicina e Scienze della Salute Vincenzo 
      Tiberio, Universita degli Studi del Molise; A. De Socio, MD, Dipartimento di 
      Medicina e Scienze della Salute Vincenzo Tiberio, Universita degli Studi del 
      Molise; F.M. Perrotta, MD, Dipartimento di Medicina e Scienze della Salute 
      Vincenzo Tiberio, Universita degli Studi del Molise.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20170601
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biological Products)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Psoriatic/*drug therapy
MH  - Biological Products/*therapeutic use
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Remission Induction
MH  - Treatment Outcome
OTO - NOTNLM
OT  - BIOLOGIC THERAPY
OT  - COMPOSITE INDICES
OT  - DMARD
OT  - PSORIATIC ARTHRITIS
OT  - REMISSION
EDAT- 2017/06/03 06:00
MHDA- 2018/05/03 06:00
CRDT- 2017/06/03 06:00
PHST- 2017/04/26 00:00 [accepted]
PHST- 2017/06/03 06:00 [pubmed]
PHST- 2018/05/03 06:00 [medline]
PHST- 2017/06/03 06:00 [entrez]
AID - jrheum.170112 [pii]
AID - 10.3899/jrheum.170112 [doi]
PST - ppublish
SO  - J Rheumatol. 2017 Aug;44(8):1159-1164. doi: 10.3899/jrheum.170112. Epub 2017 Jun 
      1.